Diligence memo · auto-generated · as of July 2, 2026

Oncology Honduras, LLC

Oncology Honduras, LLC looks fair against its niche peers and is dormant on financing cadence.

DeprioritizeFinancing has gone silent well past the sector's normal cadence — treat as inactive until outside confirmation of a live operation.

Businessfiled

Oncology Honduras, LLC operates in Pharma, based in HUNTSVILLE.

Sub-sector tags: pharma.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Oncology Honduras, LLC has raised $1.1M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).

Largest single filing: $1.1M on 2017-02-09.

Most recent recorded round closed around 2017-02-09.

Valuation (modeled)modeled

Provath models Oncology Honduras, LLC at approximately $42M (range $832K–$328M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Fair. Modeled value is 0.71× the median modeled value of Seed Pharma companies in 2016–2018 (6 peers) — value vs value, same stage and era. Within the normal band (71% of peer median) for its niche.

Financing rhythm & timingmixed

Last raise 9.4 yr ago; this sector typically re-raises about every 16 months.

Only one round on record and long silent — often defunct, acquired, or gone quiet.

Comparablesmixed

Capital scale ranks ahead of 38% of Pharma peers (310 compared).

Modeled value ranks above 54% of those peers.

Closest niche peers: Capstone Therapeutics Corp., Luma Therapeutics, Inc., Eliaz Therapeutics, Inc., Eikonizo Therapeutics, Inc., Jupiter Orphan Therapeutics, Inc..

Peoplefiled

3 named people on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.